EPIRUS Biopharmaceuticals, Inc. (NasdaqCM:EPRS) plans to use proceeds from the sale of securities for general corporate purposes, which may include commercial launch activities, sales and marketing expenditures, funding of clinical trials, research and development, regulatory activities, acquisitions of companies, products, intellectual property or other technology, investments, capital expenditures, and for any other purposes.